### UNITED STATES PATENT AND TRADEMARK OFFICE

\_\_\_\_\_

BEFORE THE PATENT TRIAL AND APPEAL BOARD

\_\_\_\_\_

NALOX-1 PHARMACEUTICALS, LLC, Petitioner,

v.

OPIANT PHARMACEUTICALS, INC., Patent Owners.

Case No. IPR2019-00695 U.S. Patent No. 9,629,965

\_\_\_\_\_

MANDATORY NOTICES OF PATENT OWNER OPIANT PHARMACEUTICALS, INC.



Pursuant to 37 C.F.R. § 42.8(a)(2), Patent Owner Opiant Pharmaceuticals, Inc. ("Opiant") submits the following mandatory notices:

## I. Real Parties in Interest, 37 C.F.R. § 42.8(b)(1)

Adapt Pharma Limited ("Adapt") and Opiant and are the assignees, and Adapt Pharma Operations Limited, a wholly owned subsidiary of Adapt, is a limited exclusive licensee, of U.S. Patent No. 9,561,177 and U.S. Patent No. 9,775,838. Opiant is the assignee, and Adapt Pharma Operations Limited is a limited exclusive licensee, of U.S. Patent No. 9,211,253; U.S. Patent No. 9,468,747; and U.S. Patent No. 9,629,965.

Adapt is a wholly owned subsidiary of Emergent Acquisitions Limited.

Emergent Acquisitions Limited is a wholly owned subsidiary of Emergent

International Inc., which is a wholly owned subsidiary of Emergent BioSolutions

Inc. Emergent BioSolutions Inc. is a publicly held company, and no publicly held
company owns 10% or more of Emergent BioSolutions Inc.'s stock. Opiant is a

publicly held company, and no publicly held company owns 10% or more of
Opiant's stock.

# II. Related Matters, 37 C.F.R. § 42.8(b)(2)

Petitioner Nalox-1 Pharmaceuticals, LLC ("Nalox-1") has filed the following related petitions for *inter partes* review:

U.S. Patent No.	Case No.
9,211,253	IPR2019-00685



U.S. Patent No.	Case No.
9,211,253	IPR2019-00686
9,211,253	IPR2019-00687
9,468,747	IPR2019-00688
9,468,747	IPR2019-00689
9,468,747	IPR2019-00690
9,561,177	IPR2019-00691
9,561,177	IPR2019-00692
9,561,177	IPR2019-00693
9,629,965	IPR2019-00694
9,629,965	IPR2019-00695
9,629,965	IPR2019-00696
9,775,838	IPR2019-00697
9,775,838	IPR2019-00698
9,775,838	IPR2019-00699

U.S. Patent No. 9,211,253; U.S. Patent No. 9,468,747; U.S. Patent No. 9,561,177; U.S. Patent No. 9,629,965; and U.S. Patent No. 9,775,838 are being asserted in *Adapt Pharma Operations Ltd., et al. v. Teva Pharmaceuticals USA, Inc., et al.*, Case 2:16-cv-07721-JLL-JAD (D.N.J.) (consolidated), filed October 21, 2016; and *Adapt Pharma Operations Ltd., et al. v. Perrigo UK FINCO Limited Partnership*, Case 2:18-cv-15287-JLL-JAD (D.N.J.), filed October 25, 2018.

Administrative matters that would be or could be affected by this proceeding include pending U.S. Patent Application Nos. 15/415,221; 15/494,270; and 16/131,641.



### III. Lead & Backup Counsel, 37 C.F.R. § 42.8(b)(3)

Opiant designates the following counsel:

### LEAD COUNSEL

Robert F. Green
Reg. No. 27,555
Green, Griffith & Borg-Breen LLP
676 North Michigan Avenue
Suite 3900
Chicago, IL 60611
Phone: (312) 883-8000
Fax: (312) 883-8001
rgreen@greengriffith.com

### BACKUP COUNSEL

Jessica Tyrus Mackay
Reg. No. 64,742
Green, Griffith & Borg-Breen LLP
676 North Michigan Avenue
Suite 3900
Chicago, IL 60611
Phone: (312) 883-8000
Fax: (312) 883-8001
jmackay@greengriffith.com

A power of attorney appointing the foregoing counsel to transact all business in this proceeding is being submitted together with this mandatory notice information.

# IV. Service Information, 37 C.F.R. § 42.8(b)(4)

Counsel for Opiant submits the following service information:



Case No. IPR2019-00695 U.S. Patent No. 9,629,965

Electronic mail address: jmackay@greengriffith.com

**Postal mail address:** Jessica Tyrus Mackay

GREEN, GRIFFITH & BORG-BREEN, LLP

676 North Michigan Avenue

**Suite 3900** 

Chicago, IL 60611

**Telephone number:** (313) 883-8000

Counsel for Opiant consents to electronic service by email at jmackay@greengriffith.com.

Date: March 12, 2019 Respectfully submitted,

/Jessica Tyrus Mackay /

Jessica Tyrus Mackay (Reg. No. 64,742) Green, Griffith & Borg-Breen, LLP

676 North Michigan Avenue

Suite 3900

Chicago, IL 60611 (313) 883-8000

jmackay@greengriffith.com

Counsel for Patent Owner Opiant Pharmaceuticals, Inc.



# DOCKET

# Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

# **Real-Time Litigation Alerts**



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## **Advanced Docket Research**



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

# **Analytics At Your Fingertips**



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

### API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

#### **LAW FIRMS**

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

#### **FINANCIAL INSTITUTIONS**

Litigation and bankruptcy checks for companies and debtors.

### **E-DISCOVERY AND LEGAL VENDORS**

Sync your system to PACER to automate legal marketing.

